Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0316181 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tatsuya Noda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Health Management and Policy, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mesalamine, Databases, Factual. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI `, Health Labour Sciences Research Grant.
Abstract (Originalsprache)
The 5-aminosalicylic acid (5-ASA) agents are first-line drugs for ulcerative colitis (UC). However, intolerance as well as other issues have been reported for these drugs, making it difficult to sustain this treatment; accordingly, the persistence of 5-ASA is an important indicator of UC treatment strategy. We aimed to analyze the persistence of 5-ASA in patients with UC in Japan. This was a 1-year, nationwide, population-based cohort study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. We identified patients who were assigned UC-related disease codes and newly prescribed 5-ASA between April 2015 and September 2019 and specified the number of days until 5-ASA prescriptions were interrupted during a follow-up of up to 365 days. Among the 137 million patients who were covered by the universal health insurance in Japan during the study period, 68,234 eligible patients were identified. The 5-ASA persistence in these patients were 87.2%, 65.6%, and 56.4% after 30, 180, and 365 days, respectively. The 5-ASA persistence by subtype at 365 days was 54.4%, 56.4%, and 57.6% for time-dependent, pH-dependent, and multi-matrix system types, respectively. The 5-ASA persistence rate after 365 days was 65.0% for those under 20 years of age, 51.0% for those 20–39 years old, 57.5% for those 40–64 years old, and 65.5% for those over 64 years of age. This study revealed the 1-year persistence of newly prescribed 5-ASA in patients with UC newly prescribed 5-ASA in Japan, based on a national claims database of more than 100 million individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Public Health, Health Management and Policy, Nara Medical University, Nara, Japan.
- Department of Public Health, Kurume University School of Medicine, Fukuoka, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
- Department of Public Health Policy, National Institute of Public Health, Saitama, Japan.
- Initiative for Clinical Epidemiological Research, Tokyo, Japan.
ORCID-Profile: Tatsuya Noda, Kotaro Kuwaki, Tomoya Myojin
Förderung
- JSPS KAKENHI `
- Health Labour Sciences Research Grant
Zitieren
APA
Noda, T., Kuwaki, K., Machida, M., Okumura, Y., Nishioka, Y., Myojin, T., & Imamura, T. (2024). Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study. PLOS ONE. https://doi.org/10.1371/journal.pone.0316181
Vancouver
Noda T, Kuwaki K, Machida M, Okumura Y, Nishioka Y, Myojin T, et al. Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study. PLOS ONE. 2024. doi:10.1371/journal.pone.0316181
BibTeX
@article{Noda2024,
author = {Noda, Tatsuya and Kuwaki, Kotaro and Machida, Munehito and Okumura, Yasuyuki and Nishioka, Yuichi and Myojin, Tomoya and Imamura, Tomoaki},
title = {Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0316181}
}
EUVIMED